Skip to main content

SICK DAYS- SITUATIONS REQUIRING HOSPITALIZED CARE!

SITUATIONS REQUIRING HOSPITALIZED CARE

  • The NICE-SUGAR (Intensive versus conventional glucose in critically ill patients) trial compared intensive (81-108 mg/dL) with conventional glucose control using IV Insulin in 6104 intensive care unit patients.
  • At 90 days, intensively controlled patients had an increased absolute risk of death of 2.6%.
  • Significantly, more hypoglycemia was observed in intensively controlled group.

Recommendations:

  • Current recommendations call for critically ill patients to be started on IV Insulin therapy at a threshold of 180mg/dL.
  • A goal range of 140-180mg/dL is recommended for majority of patients.
  • More stringent goals may be considered for selected critically ill patients, but only if hypoglycemia can be avoided.
  • Scheduled SC insulin regimens with basal, nutritional and correction components are recommended for patients who are not critically ill.
  • Goals of less than 140mg/dL for fasting glucose and less than 180mg/dL for random glucose are recommended for non-critically ill patients.

  • Patients should monitor their blood glucose levels more frequently during the sick days because it is more common for illness to increase blood glucose values.
    • Patients with T1 DM should check their glucose and urine for ketones every 4 hours when sick.
    • Patients with T2 DM may also need to check for ketones when their blood glucose levels are greater than 300mg/dL.
    • Patients should continue to take their medications while sick.
    • T1 DM patients may require additional insulin coverage, and some with T2 DM who are currently on, or medication regimens may require insulin during an acute illness.
    • Patients should be advised to maintain their normal caloric intake and carbohydrate intake while ill as well as to drink plenty of non-caloric beverages to avoid dehydration.
    • When having difficulty eating a normal diet, patients may be advised to use non-diet beverages, soft drinks, broths, crackers, soup, and non-diet gelatins to provide normal caloric and carbohydrate intake and avoid hypoglycemia.
    • With proper management, patients can decrease their chances of illness-induced hospitalization, particularly Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State.

    Measurement of Blood Glucose Levels:

    Several methods can be used for measuring Blood glucose levels.

    • Arterial samples are usually 5mg/dL higher than capillary values and 10mg/greater than venous values.
    • When preparing an insulin infusion for a patient, several factors must be considered, insulin will absorb to glass and plastic, reducing the amount of insulin actually delivered by 20%-30%. Primarily, the tubing decreases the variability of insulin infused.
    • Therefore, when patients can be converted safely from infusion to needle and syringe therapy, the total daily dose should be reduced by 20%to 50% of the daily infusion amount.
    • When transferring someone from IV insulin drip to subcutaneous insulin, basal insulin should be administered several hours before the drip is discontinued to prevent loss of glycemic control.
    • IV drip protocols are institution specific.


    Labels

    Labels:

    Comments

    Post a Comment

    Popular posts from this blog

    Diabetes Mellitus: Pharmacotherapy- Gliptins and a-Glycoside Inhibitors!

      PHARMACOTHERAPY:  Medications classifications include:  Sulfonyl Urea's Nonsylfonylurea Secretagogues (a-Glinides) Biguanides Thiazolidinediones a-Glucosidase Inhibitors Dipeptidyl Peptidase-4 Inhibitors (Gliptins) Sodium-glucose co-transporter (SGLT) Inhibitors  Central-Acting Dopamine Agonists Bile Acid Sequestrants Insulin therapy 5. a-GLUCOSIDASE INHIBITORS Acarbose and Miglitol are a-glucosidase inhibitors currently approved in the United States. Mechanism of Action: An enzyme that is along the brush border of the intestine cells called a-glucosidase; breaks down the complex carbohydrates into simple sugars, resulting in absorption. The a-glucosidase inhibitors work by delaying the absorption of carbohydrates from the intestinal tract, which reduces the rise in postprandial glucose levels. Therapy: As a monotherapy , a-glucosidase inhibitors primarily reduce post-prandial glucose excursions.  Clinical Use: FPG concentrations have been decreased by 40-5...
    Post a Comment
    Read more

    Diabetes Mellitus: Types!

    TYPES OF DIABETES MELLITUS 1. TYPE1 DM Type 1 DM is usually diagnosed before age 30 years, but it can develop at any age. T1DM is an autoimmune disease in which insulin producing B-cells are destroyed. The presence of Human Leucocyte Antigens (HLAs ) is associated with the development of T1DM. In addition, these individuals often develop Islet cell antibodies , Insulin Autoantibodies or Glutamic Acid decarboxylase autoantibodies . At the time of development of diagnosis of T1DM, it is usually believed that most of the patients have 80-90%loss of beta cells. The remaining beta cells function at the diagnosis creates a " HONEYMOON PERIOD" during which the blood glucose levels are easier to control, and smaller amounts of insulin are required. after this, the remaining beta cells function is completely lost, and the patients become completely deficient of insulin and hence require exogenous insulin.  2. TYPE1.5 DM:  Also referred as Latent autoimmune diabetes in Adults (LAD) ...
    Post a Comment
    Read more

    Diabetes Mellitus: Etiology and Epidemiology!

     DIABETES MELLITIS Definition: Diabetes Mellitus (DM) describes a group pf chronic metabolic  disorders characterized by hyperglycemia that may result in long-term microvascular, macrovascular and neuropathic complications. these complications contribute to diabetes being the leading cause of: a) new cases of blindness among adults b) end stage renal diseases c)non-traumatic lower limb amputations Etiology: The increasing prevalence is caused by three influences: 1. ethnicity        2. Lifestyle       3. Age Types: a) Type 1 DM b) Type 2 DM c) Type 1.5DM d) Gestational Diabetes Mellitus (GDM) ** In type 1 DM; the body fails to make insulin. In type 2 DM; body either develops resistance to insulin or not enough insulin is produced to lower the Blood glucose levels** Epidemiology The worldwide prevalence of DM has risen over past two decades with an estimation of 30 million cases in 1985 to 177 million cases in 2000. Based on current trend...
    Post a Comment
    Read more